Johnson & Johnson (JNJ)
Johnson & Johnson - ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
Johnson & Johnson (JNJ)
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
Takeda Pharmaceutical Co Ltd (TAK)
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb - Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
Bristol-Myers Squibb Company (BMY)
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
Bristol-Myers Squibb Co. (BMYMP)
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
BRISTOL MYERS SQUIBB CO (BMY)
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
VISA INC. (V)
Visa, Street Soccer USA and Bank of America to Bring Visa Street Soccer Parks to Every FIFA World Cup 2026™ Host City in the U.S.
ROCKET LAB CORP (RKLB)
Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency
KYNDRYL HOLDINGS, INC. (KD)
Kyndryl Holdings, Inc. Notice of April 13, 2026 Application Deadline for Class Action Lawsuits - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline